In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical ...

In this trial, patients will be randomized to petosemtamab monotherapy or investigator's choice of single agent chemotherapy or cetuximab. This was detailed ... primarily as a result of decreases in ...

Eli Lilly plans to invest $27 billion in four new pharmaceutical manufacturing facilities in the U.S., expanding its domestic production of medications across multiple therapeutic areas.